Omnicell (NASDAQ:OMCL) Given “Buy” Rating at Benchmark

Benchmark reissued their buy rating on shares of Omnicell (NASDAQ:OMCL) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $62.00 price target on the stock.

Several other equities analysts have also recently commented on the stock. Wells Fargo & Company lowered their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Craig Hallum raised their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Barclays boosted their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $52.33.

Omnicell Stock Performance

OMCL stock opened at $43.85 on Tuesday. The firm has a 50 day simple moving average of $44.64 and a 200 day simple moving average of $43.10. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The stock has a market cap of $2.03 billion, a P/E ratio of -112.43, a P/E/G ratio of 30.78 and a beta of 0.78.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.64% of the company’s stock.

Institutional Trading of Omnicell

Several hedge funds have recently added to or reduced their stakes in OMCL. Van ECK Associates Corp lifted its holdings in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after buying an additional 315 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. First Horizon Advisors Inc. grew its position in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after purchasing an additional 355 shares during the last quarter. KBC Group NV increased its holdings in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after purchasing an additional 778 shares during the period. Finally, 1620 Investment Advisors Inc. raised its position in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.